Anti-TNF-alpha therapy with infliximab in spondyloarthritides. - Wikidata - wikimedia - TriplyDB

Anti-TNF-alpha therapy with infliximab in spondyloarthritides.

Anti-TNF-alpha therapy with infliximab in spondyloarthritides.

http://www.wikidata.org/entity/Q37729028

about

A pilot study of the association of tumor necrosis factor alpha polymorphisms with psoriatic arthritis in the Romanian population.Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review.Management of patients with inflammatory bowel disease and spondyloarthritis.

P2860

Q35229490-B7CC4B6C-C949-4DE0-BEF1-07971997522B Q38246381-6387DF4B-F9CE-4BF4-B020-A43EEB7BD8CC Q40054186-BA879CA2-441B-4D98-8B0A-2084B731F583

P2860

Anti-TNF-alpha therapy with infliximab in spondyloarthritides.

http://www.wikidata.org/entity/Q37729028

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Anti-TNF-alpha therapy with infliximab in spondyloarthritides.

@en

Anti-TNF-alpha therapy with infliximab in spondyloarthritides.

@nl

type

label

Anti-TNF-alpha therapy with infliximab in spondyloarthritides.

@en

Anti-TNF-alpha therapy with infliximab in spondyloarthritides.

@nl

prefLabel

Anti-TNF-alpha therapy with infliximab in spondyloarthritides.

@en

Anti-TNF-alpha therapy with infliximab in spondyloarthritides.

@nl

P1433

Q37729028-DF332328-D65D-4887-AA4C-51D776AB1F08

P1476

Q37729028-48A83893-2A53-42C2-A40F-5F0C8CCEA10A

P2093

Q37729028-49FEAB9E-1EB9-4B88-A5DE-EC630B4158FD

Q37729028-B5BA50E7-ECBF-4C6E-91FE-070D5F55E1E3

P2860

Q37729028-02A3EBB8-F825-48A6-927D-C78E6BDD8915

Q37729028-068D4896-4EC7-41D9-9D16-B67F02A0A3A4

Q37729028-0C9226EA-42B8-4BA3-9C35-B140036BC535

Q37729028-0CE24201-CB18-4CBD-9B98-0DB362542B5A

Q37729028-0D0A470D-FE1E-4AA6-BE97-8774955A16D4

Q37729028-14C36FBF-F5FD-40A8-9F7A-72870BBBA15D

Q37729028-155C9D56-DFB6-42A9-B2AF-E551367C0906

Q37729028-155E5786-FEED-4287-BB82-B62E90AC8571

Q37729028-170917AF-0340-4C0A-B218-3987F5CB1CFA

Q37729028-190F8FF8-51D8-482D-8F8B-78F9A8C91324

P304

Q37729028-B26A266E-0A92-4D0D-8F77-20B37B52A5BE

P31

Q37729028-026CAD9F-8CBE-4BB9-8450-7554A1891DCE

P356

Q37729028-B57E4254-9E6F-46C9-946B-87AE1817DBD8

P433

Q37729028-0954FA0C-9E3A-4C27-AE4B-D27AA0AE1482

P478

Q37729028-B13FF3C7-0659-45C9-96D9-9640895E6273

P577

Q37729028-6B8F2574-7E44-4FB2-AFBB-19926E1ABD5B

P698

Q37729028-CB5434F9-EBE1-456F-B551-4D5DCEF89440

P921

Q37729028-0D192033-C99F-470F-AF82-F30BB34057A6

Q37729028-1A60732D-107B-4D6B-BDC3-709DDA32D575

P356

P1433

Expert Review of Clinical Immunology

P1476

Anti-TNF-alpha therapy with infliximab in spondyloarthritides.

@en

P2093

Juergen Braun

http://www.w3.org/2001/XMLSchema#string

Xenofon Baraliakos

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromsø, northern Norway

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

P304

9-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECI.09.61

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20383886

http://www.w3.org/2001/XMLSchema#string

P921